Risk Management System meets pharma company needs.
Share:
Press Release Summary:
Leveraging Structured Signal Management (SSM) approach Argus Safety(TM) Suite v5.0 global drug safety and risk management system ensures medical reviewers get advanced notice of signals to promote earlier risk identification. Stable and efficient Argus database ensures pharmaceutical companies can process and manage all of their reporting obligations. Surveillance teams follow signal and risk management process according to company-defined SOPs within integrated environment.
Original Press Release:
Relsys International Announces the Release of the Argus Safety(TM) Suite 5.0
IRVINE, Calif., March 18 -- Relsys International today announced the release of the Argus Safety Suite 5.0, the new standard in global Drug Safety & Risk Management systems. The Argus Safety Suite 5.0 is a full stack release.
Argus Safety 5.0 features important productivity and usability enhancements to the most widely used adverse events management system in the world. It also features ongoing performance enhancements to the highly stable and efficient Argus database, ensuring that pharma companies can rapidly process and manage all of their reporting obligations.
Argus Perceptive 5.0 is a leading risk management system, pioneering the Structured Signal Management (SSM) approach. Argus Perceptive 5.0 enables powerful risk assessments with greater data accuracy, ensuring that medical reviewers get advanced notice of signals and potentially leading to earlier risk identification. While adhering to the Structured Signal Management approach, pharma companies ensure that their surveillance teams follow the signal and risk management process according to company-defined SOPs within an integrated environment.
Bruce Palsulich, Chief Innovation & Strategy Officer at Relsys, commented, "Increasing regulatory scrutiny and greater physician/consumer awareness have led directly to a record number of adverse events reported to regulators. In fact, in the first quarter of 2008, the FDA received a record number of adverse event reports, 82% of which originated from manufacturers. Pharma companies are struggling to meet this burden and are increasingly looking to commercial drug safety databases to help manage their regulatory requirements. I believe this is exactly why more than 1 out of every 3 of the Top 100 pharma have selected Argus Safety from Relsys to manage their pharmacovigilance obligations." Palsulich continued, "Furthermore, pharma is learning that signal detection tools by themselves do not solve their problems. Many companies now realize that Structured Signal Management provides a framework to transform large amounts of data into useful and actionable information. This is how Argus Perceptive adds true value to the science of signal detection."
Parties interested in learning more about the Argus Safety(TM) Suite 5.0 may visit the Relsys at the DIA EuroMeeting (booth #1240) in Berlin, Germany or may request a copy of the Structured Signal Management white paper via email at info@relsys.net.
About Relsys International
Relsys International provides the industry-leading Argus Safety Suite, a complete solution for pharmacovigilance and risk management that helps pharmaceutical, biotech and medical device companies improve product safety and ensure ongoing compliance with global regulations. The company, founded in 1987, works in partnership with its customers to develop and deliver innovative solutions to long-term business needs, and to provide critical components to support its clients' corporate risk management strategies. Argus Safety(TM), the company's flagship product, is the world's best selling adverse event reporting software, and is used by more of the leading pharmaceutical companies than any other solution. Relsys is a privately held company, headquartered in Irvine, California. For more information, visit relsys.net, or call +1 949-453-1715.
CONTACT: Abdul Rastagar of Relsys International, +1-949-453-1715
